Predictive biomarkers of ipilimumab toxicity in metastatic melanoma.

Volume: 35, Issue: 15_suppl, Pages: 9559 - 9559
Published: May 20, 2017
Abstract
9559 Background: There are no predictive biomarkers of ipilimumab (IPI) toxicity. Of metastatic melanoma (MM) patients (pts) receiving IPI (3mg/kg), 35% require systemic therapies to treat immune-related adverse events (irAEs) and 20% must terminate treatment (Horvat et al., JCO 2015). Here we tested the hypothesis that a pre-existing autoantibody (autoAb) profile is predictive of IPI irAEs. Methods: We measured autoAb levels in pre- and...
Paper Details
Title
Predictive biomarkers of ipilimumab toxicity in metastatic melanoma.
Published Date
May 20, 2017
Volume
35
Issue
15_suppl
Pages
9559 - 9559
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.